ZA202200905B - Anti-egfr/anti-4-1bb bispecific antibody and use thereof - Google Patents

Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Info

Publication number
ZA202200905B
ZA202200905B ZA2022/00905A ZA202200905A ZA202200905B ZA 202200905 B ZA202200905 B ZA 202200905B ZA 2022/00905 A ZA2022/00905 A ZA 2022/00905A ZA 202200905 A ZA202200905 A ZA 202200905A ZA 202200905 B ZA202200905 B ZA 202200905B
Authority
ZA
South Africa
Prior art keywords
bispecific antibody
egfr
cancer
treating
preventing
Prior art date
Application number
ZA2022/00905A
Other languages
English (en)
Inventor
Yong Yeryoung
Jung Ui-Jung
Chung Hyejin
Park Kyeongsu
Son Wonjun
Lee Yangsoon
Kim Yeunju
Sung Eunsil
Kim Youngkwang
Pak Youngdon
Park Minji
Eom Jaehyun
Choi Hyoju
Young Song Moo
Rae Lee Na
Bong Park Young
Lee Eun-Jung
Original Assignee
Abl Bio Inc
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc, Yuhan Corp filed Critical Abl Bio Inc
Publication of ZA202200905B publication Critical patent/ZA202200905B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2022/00905A 2019-07-26 2022-01-19 Anti-egfr/anti-4-1bb bispecific antibody and use thereof ZA202200905B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878977P 2019-07-26 2019-07-26
PCT/KR2020/009870 WO2021020845A1 (en) 2019-07-26 2020-07-27 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
ZA202200905B true ZA202200905B (en) 2023-11-29

Family

ID=74189704

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/00905A ZA202200905B (en) 2019-07-26 2022-01-19 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Country Status (11)

Country Link
US (2) US12168690B2 (https=)
EP (1) EP4004053A4 (https=)
JP (2) JP7738545B2 (https=)
KR (1) KR20220038767A (https=)
CN (2) CN118221825A (https=)
AU (1) AU2020320349A1 (https=)
BR (1) BR112022001329A2 (https=)
CA (1) CA3147420A1 (https=)
MX (1) MX2022001027A (https=)
WO (1) WO2021020845A1 (https=)
ZA (1) ZA202200905B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US20250320309A1 (en) * 2021-11-25 2025-10-16 Shenghe (China) Biopharmaceutical Co., Ltd. Bispecific antigen binding protein
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
JP2025542406A (ja) * 2022-12-30 2025-12-25 アブクロン・インコーポレイテッド Ｃｄ１３７に特異的に結合するアフィボディ及びその用途
KR20240164748A (ko) * 2023-05-12 2024-11-20 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체
KR102927129B1 (ko) 2025-03-18 2026-02-11 이트너스 주식회사 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185770T3 (es) * 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AU2006211037B2 (en) 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
JP6539275B2 (ja) * 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
FI3436048T3 (fi) 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
SG11202000503QA (en) * 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN119798453A (zh) * 2018-11-13 2025-04-11 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
PE20211147A1 (es) * 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CA3169943A1 (en) * 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof

Also Published As

Publication number Publication date
JP2022542670A (ja) 2022-10-06
CN118221825A (zh) 2024-06-21
MX2022001027A (es) 2022-04-18
JP2026004296A (ja) 2026-01-14
KR20220038767A (ko) 2022-03-29
CA3147420A1 (en) 2021-02-04
AU2020320349A1 (en) 2022-02-17
US20250066487A1 (en) 2025-02-27
CN114450306A (zh) 2022-05-06
JP7738545B2 (ja) 2025-09-12
US20210024638A1 (en) 2021-01-28
EP4004053A4 (en) 2023-10-18
CN114450306B (zh) 2024-04-05
US12168690B2 (en) 2024-12-17
BR112022001329A2 (pt) 2022-03-22
EP4004053A1 (en) 2022-06-01
WO2021020845A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CA3284664A1 (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
NZ795271A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
PH12022550932A1 (en) Glp-1r modulating compounds
MY199303A (en) Kras g12c inhibitors and methods of using the same
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
WO2020257823A3 (en) TGF-β RECEPTORS AND METHODS OF USE
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2021003168A (es) Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico.
ZA202309150B (en) Antibody against nkp46 and application of antibody
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
EP4062934A4 (en) COMPOSITION FOR PREVENTING OR TREATING CANCER WITH ANTI-CD300C MONOCLONAL ANTIBODIES
EP4048700A4 (en) BISPECIFIC ANTI-BCMA/ANTI-4-1BB ANTIBODIES AND THEIR USES
EP4019657A4 (en) Steel, and method for producing same
MX2024004871A (es) Compuesto que contiene piridilo.